Business

Announcement on Receipt of Clinical Trial Approval Notice for KC1036 in Combination with PD-1 Antibody and Platinum-based Chemotherapy as First-Line Treatment for Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Announcement on Receipt of Clinical Trial Approval Notice for KC1036 in Combination with PD-1 Antibody and Platinum-based Chemotherapy as First-Line Treatment for Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

articleBeijing Konruns Pharmaceutical Co., Ltd. Class ASeptember 29, 20253/news/announcement-on-receipt-of-clinical-trial-approval-notice-for-kc1036-in-combination-with-pd-1-antibody-and-platinum-based-chemotherapy-as-first-line-treatment-for-advanced-recurrent-or-metastatic-esophageal-squamous-cell-carcinoma
Announcement on Receipt of Clinical Trial Approval Notice for KC1036 in Combination with PD-1 Antibody and Platinum-based Chemotherapy as First-Line Treatment for Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

About this update from Beijing Konruns Pharmaceutical Co., Ltd. Class A

Announcement on Receipt of Clinical Trial Approval Notice for KC1036 in Combination with PD-1 Antibody and Platinum-based Chemotherapy as First-Line Treatment for Advanced Recurrent or Metastatic Esophageal Squamous Cell CarcinomaThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Beijing Konruns Pharmaceutical Co., Ltd. Class A